Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $10.1 million.

  • Akebia Therapeutics' Accounts Payables fell 2524.83% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 2524.83%. This contributed to the annual value of $15.2 million for FY2024, which is 372.39% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Accounts Payables is $10.1 million, which was down 2524.83% from $11.6 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Accounts Payables high stood at $42.0 million for Q2 2021, and its period low was $9.0 million during Q3 2023.
  • Moreover, its 5-year median value for Accounts Payables was $14.6 million (2023), whereas its average is $18.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 5414.05% in 2023, then skyrocketed by 4930.29% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Accounts Payables (Quarter) stood at $33.6 million in 2021, then tumbled by 46.35% to $18.0 million in 2022, then decreased by 18.79% to $14.6 million in 2023, then rose by 3.72% to $15.2 million in 2024, then plummeted by 33.55% to $10.1 million in 2025.
  • Its Accounts Payables stands at $10.1 million for Q3 2025, versus $11.6 million for Q2 2025 and $12.7 million for Q1 2025.